Cephalexin 500 mg Twice Daily for 5 Days is Appropriate for Uncomplicated Nonpurulent Cellulitis
For uncomplicated nonpurulent cellulitis in a healthy adult, cephalexin 500 mg twice daily for 5 days is an appropriate and evidence-based treatment regimen, provided the patient can self-monitor and has close follow-up.
Rationale and Evidence
Duration: 5 Days is Sufficient
The 2021 American College of Physicians guidelines explicitly recommend a 5- to 6-day course of antibiotics active against streptococci for nonpurulent cellulitis 1. This represents the most recent high-quality guideline evidence and supersedes older recommendations. The 2014 IDSA guidelines suggested 5-10 days, noting that treatment could be as short as 5 days if clinical improvement occurred 2. Multiple RCTs have demonstrated no significant difference in clinical outcomes between 5-6 day courses versus longer 10-14 day courses 1.
Antibiotic Choice: Cephalexin is First-Line
For nonpurulent cellulitis (no purulent drainage, no abscess), empirical therapy targeting β-hemolytic streptococci is recommended 3, 4, 3. The guidelines specifically list cephalexin as an appropriate β-lactam option 1, 2. MRSA coverage is typically unnecessary for typical nonpurulent cellulitis unless the patient fails to respond to β-lactam therapy 3, 4.
Dosing: Twice Daily is Effective
Cephalexin 500 mg twice daily is FDA-approved and clinically validated for skin and skin structure infections 5. Multiple studies from the 1980s-1990s demonstrated that twice-daily cephalexin (500 mg or 1 g) achieved cure rates exceeding 90-97% for skin infections, equivalent to four-times-daily dosing 6, 7, 8, 9. A 2025 study confirmed twice-daily cephalexin showed no statistically significant difference in treatment failure compared to four-times-daily dosing 10. The twice-daily regimen enhances compliance while maintaining efficacy.
Clinical Algorithm
Use this regimen when:
- Cellulitis is nonpurulent (no pus, no drainable abscess)
- Patient is otherwise healthy (no immunosuppression, no comorbidities)
- No systemic toxicity (no high fever, hypotension, or delirium)
- No risk factors for MRSA (no injection drug use, no penetrating trauma, no known MRSA colonization)
- Patient can self-monitor symptoms
- Close follow-up within 48-72 hours is available
Modify treatment if:
- No improvement by day 3-5: Consider adding MRSA coverage (TMP-SMX or doxycycline) or switching to clindamycin 3, 4
- Worsening symptoms: Re-evaluate for abscess formation, deeper infection, or alternative diagnosis
- Systemic signs develop: Consider hospitalization and IV antibiotics
Important Caveats
The infection may initially worsen in the first 24-48 hours after starting antibiotics due to bacterial lysis releasing inflammatory enzymes 2. This does not necessarily indicate treatment failure.
Elevation of the affected area is essential to promote drainage of edema and inflammatory mediators 2.
Address predisposing factors such as tinea pedis, venous insufficiency, or trauma to prevent recurrence 2.
MRSA is an uncommon cause of typical cellulitis—a prospective study showed 96% success with β-lactam monotherapy in a high-MRSA setting 2. Empiric MRSA coverage is not routinely needed for nonpurulent cellulitis 3, 4, 3.
Divergent Evidence
While the 2011 IDSA guidelines recommended 5-10 days 3, 4, 3, the 2021 ACP guidelines provide more definitive support for the shorter 5-6 day duration based on newer RCT data 1. The DANCE trial (2021) comparing 6 versus 12 days showed similar cure rates, though confidence intervals were wide 1. Given the antimicrobial stewardship imperative and equivalent outcomes, the shorter duration is preferred when clinical improvement is evident by day 5.